Dallah Healthcare Co. (4004) is listed on Tadawul of the Saudi Exchange (Tadawul) under sector Health Care Equipment & Svc. Financial data sourced from CMA-mandated XBRL filings via Sahm Screener (sahmscreener.com).

For fiscal year 2024, Dallah Healthcare Co. reported revenue of SAR 3.21B, net profit of SAR 485M, and earnings per share of SAR 4.83. Total assets stood at SAR 6.61B with total equity of SAR 3.47B and total liabilities of SAR 2.87B.

Operating cash flow for 2024 was SAR 678M, representing a cash conversion ratio of 1.40 relative to net profit. Free cash flow was SAR 321M.

Earnings quality analysis by Sahm Screener: Of every SAR 1.00 in reported net profit for 2024, SAR 1.40 arrived as operating cash. This indicates Exceptional quality earnings based on the cash conversion ratio of 1.40.

Revenue growth from 2023 to 2024: +8.9%. Net profit growth over the same period: +25.9%. 3-year revenue CAGR: 33.6%. 3-year net profit CAGR: 20.9%.

Key financial ratios for 2024: Return on Equity 14.0%, Return on Assets 7.3%, Net Margin 15.1%, Debt to Equity 0.83.

In 2023, Dallah Healthcare Co. reported revenue of SAR 2.94B and net profit of SAR 385M, compared to SAR 3.21B and SAR 485M respectively in 2024.